Houfu Qian
Xiang Tao
Li Yuan
Xin Wang
Bing Yu- 1Department of Gastroenterology, Taizhou Second People’s Hospital, Taizhou, Jiangsu, China
- 2Department of Cell Biology, Naval Medical University, Shanghai, China
- 3Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
- 4Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, China
- 5Molecular and Cellular Therapeutics, University of Minnesota Twin Cities, StPaul, United States
Editorial on the Research Topic
Applications of medicinal plants and their metabolites in fibrotic disease: novel strategies, mechanisms, and their impact on clinical practice
Fibrotic diseases represent a major global health challenge. They are pathologically characterized by the excessive deposition of the extracellular matrix, which ultimately leads to organ dysfunction and failure (Zhao et al., 2022; Kim T. R. et al., 2025). Current therapeutic options remain severely limited, with only a few anti-fibrotic agents approved for clinical use. Examples include pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) and the more recently approved resmetirom for non-alcoholic steatohepatitis (NASH)-related liver fibrosis (Ahangari et al., 2022; Harrison et al., 2024). However, the utility of these drugs is considerably constrained by issues including significant gastrointestinal side effects and poor patient tolerance, which markedly limit their clinical efficacy and long-term adherence. In response to these challenges, natural products derived from medicinal plants and fungi, with their innate “structural diversity–multi-components–multi-targets” synergy, excellent biocompatibility, and safety profiles, have emerged as a highly promising new direction in the research on therapies for fibrotic diseases (Kuete et al., 2025; Li et al., 2025).
This Research Topic presents eight insightful contributions (Table 1) that collectively advance our understanding of the molecular mechanisms and therapeutic potential of natural compounds in diverse fibrotic contexts, spanning liver, lung, kidney, intestinal, and systemic fibrotic diseases. Each study highlights novel strategies and pathways, reinforcing the translational promise of medicinal plants and their metabolites in fibrosis management.
Table 1. Overview of the eight featured articles in this Research Topic.
The study by Yang et al. demonstrates that rhaponticin (RHA) alleviates liver fibrosis in a carbon tetrachloride-induced rat model by improving liver function, inhibiting the activation of hepatic stellate cells, and reducing collagen deposition. Non-targeted metabolomics revealed the modulation of multiple metabolic pathways, particularly those of glycerophospholipids, phenylalanine, and tryptophan, suggesting a multi-targeted mechanism underlying RHA’s therapeutic effects. These findings not only provide robust evidence supporting RHA as a promising natural product for anti-liver fibrosis therapy but also deepen our understanding of the metabolic mechanisms underlying liver fibrosis, offering important insights for future research in this field.
The review by Ma et al. offers a comprehensive and insightful overview of idiopathic pulmonary fibrosis (IPF). It integrates key pathogenic mechanisms, such as epithelial injury, fibroblast-to-myofibroblast transition, ECM dysregulation, and key signaling cascades including TGF-β/Smad and NF-κB, with a systematic survey of over 20 anti-fibrotic natural products from terrestrial and marine sources. A particular strength of this article lies in its organization of diverse natural compounds, including flavonoids, saponins, polyphenols, and marine alkaloids, according to their multi-target mechanisms, which helps clarify their therapeutic relevance. Notably, the authors do not shy away from addressing translational challenges, such as bioavailability and mechanistic complexity, while also outlining how advanced tools such as high-throughput screening and Artificial Intelligence (AI)-assisted drug design could accelerate future discovery. By bridging molecular pathogenesis, natural product pharmacology, and cutting-edge technology, this review offers a structured and forward-looking perspective that will be valuable for researchers exploring novel IPF therapeutics.
The study by Xiong et al. offers valuable insights into the anti-fibrotic mechanism of Jingtian Granule (JT) in chronic kidney disease. Using an adenine-induced mouse model, the authors demonstrate that JT ameliorates renal fibrosis through the activation of the mitochondrial deacetylase SIRT3, which deacetylates the tumor suppressor P53, thereby suppressing ferroptosis and lipid peroxidation. SIRT3 knockout abrogated JT’s protective effects, confirming its pivotal role. In vitro experiments with HK-2 cells corroborated these findings by modulating ROS and the SIRT3/P53/GPX4 axis. Importantly, this research bridges traditional Chinese medicine with modern cell death mechanisms, revealing a novel link between ferroptosis inhibition and renal anti-fibrotic therapy. The identification of the SIRT3/P53 axis not only elucidates a sophisticated molecular pathway but also highlights its potential as a therapeutic target for CKD treatment.
The review by Li et al. provides a comprehensive analysis of the cellular and molecular mechanisms driving intestinal fibrosis in inflammatory bowel disease (IBD). It effectively elucidates the roles of inflammatory cells (eosinophils, mast cells, macrophages), profibrotic cytokines (IL-17, IL-6, IL-34), and gut microbiota metabolites in fibrosis progression. The authors also examine current and potential therapeutic agents, including mesenchymal stem cells, PPAR-γ agonists, and pirfenidone, with an emphasis on traditional Chinese medicine and its multi-target advantages. Furthermore, lifestyle interventions such as dietary modulation and vitamin D supplementation are proposed as adjunctive strategies, advocating integrative approaches to IBD-related fibrosis management. By bridging molecular mechanisms with holistic treatment approaches, this review makes a valuable contribution to the evolving paradigm of IBD-related fibrosis therapy.
The study by Zhang et al. presents a compelling investigation into the anti-fibrotic synergistic effects of polydatin and curcumin (PD + Cur) in a bleomycin-induced model of connective tissue disease-associated interstitial lung disease (CTD-ILD). Using multi-omics approaches, the authors convincingly demonstrate that PD + Cur alleviates alveolar damage and fibrosis by activating GABBR, leading to downstream suppression of the PI3K/AKT/TGF-β signaling axis. Further pharmacological validation using GABBR agonists and antagonists solidifies the mechanistic link between target engagement and therapeutic outcome. These findings not only reveal a novel role for GABBR in fibrotic lung disease but also highlight the promise of natural product combinations as multi-target strategies for treating CTD-ILD.
The review by Chen et al. provides an authoritative overview of pharmacological strategies for liver fibrosis, systematically cataloging interventions from conventional drugs, repurposed drugs, plant-derived metabolites, and traditional Chinese formulas. Notably, the authors highlight promising advanced approaches, such as combination therapies, extracellular vesicles, and nanotechnology, for enhancing targeting precision. While acknowledging encouraging preclinical and clinical results, the review also critically identifies persistent gaps, including the lack of standardized efficacy assessment and large-scale validation. By emphasizing the need for rigorous clinical trials and improved translational frameworks, this work constructively outlines a pathway to bridge the gap between natural product research and clinically applicable liver fibrosis therapies.
The review by Zhao et al. comprehensively analyzes icariin (ICA) as a multi-organ anti-fibrotic agent, covering fibrosis in the lung, heart, kidney, liver, bladder, skin, and arachnoid membrane. The authors delineate ICA’s pleiotropic mechanisms, which range from anti-inflammatory and antioxidant effects to the regulation of mitochondrial function, cell death, autophagy, and macrophage polarization, through key pathways, including TGF-β/Smad, NF-κB, AMPK, Nrf2/HO-1, and WNT/β-catenin. The authors not only present compelling preclinical evidence but also critically address pharmacokinetic limitations, highlighting advanced extraction methods and nano-delivery strategies to overcome bioavailability challenges. While the preclinical profile is notably robust, the review appropriately emphasizes the crucial need for clinical validation. This contribution successfully positions ICA as a promising multi-target natural product while constructively outlining the translational pathway from mechanistic understanding to potential clinical application.
The study by Yin et al. presents a mechanistically insightful investigation into the anti-fibrotic properties of fangchinoline (FAN) in a diethylnitrosamine-induced liver fibrosis model. The authors demonstrate that FAN attenuates liver injury and collagen deposition by inhibiting stellate cell activation and extracellular matrix protein expression, and also reveal that FAN regulates taurine metabolism by specifically restoring CSAD enzyme expression and hepatic taurine levels. Taurine synergistically enhances FAN’s anti-fibrotic effect by reducing reactive oxygen species and activating the Nrf2 antioxidant pathway. Combined treatment with the ROS scavenger N-acetylcysteine further potentiated these effects. Thus, this study not only delineates a taurine-mediated mechanism for FAN but also highlights the therapeutic potential of targeting metabolic pathways in liver fibrosis.
As a multifaceted pathological process driven by numerous factors and signaling cascades, fibrosis inherently necessitates multi-target therapeutic strategies (Antar et al., 2023). The findings presented in this Research Topic strongly support the role of medicinal plants and their bioactive metabolites as promising sources for such interventions. These natural agents demonstrate the ability to concurrently modulate key processes in fibrosis, including metabolic reprogramming, ferroptosis, immune responses, oxidative stress, and critical signaling pathways, thereby validating their potential for comprehensive therapeutic intervention. This multi-target capacity represents a distinct advantage over single-target agents, because it aligns more closely with the complex pathogenesis of fibrotic diseases.
However, the current body of evidence remains largely confined to preclinical studies, characterized by limited sample sizes and a predominant reliance on in vitro and animal models. The critical absence of clinical trial data constitutes a major bottleneck to translation. Further complicating this transition are the inherent challenges of natural products, such as suboptimal physicochemical properties (e.g., poor solubility, low bioavailability, and a short half-life), complex pharmacokinetics, and difficulties in standardization (Kim H. K. et al., 2025; Liu H. et al., 2025; Liu X. et al., 2025).
To bridge this gap, a convergent research paradigm is urgently needed. Future work should integrate traditional medical knowledge with advanced technological platforms—such as multi-omics, nanomedicine, and AI—to optimize drug delivery, validate mechanisms of action, and ultimately power rigorous clinical trials. We hope this Research Topic will inspire innovative approaches that bridge ethnopharmacology and modern science, ultimately advancing effective anti-fibrotic therapies into clinical practice.
Author contributions
HQ: Writing – original draft, Writing – review and editing. XT: Formal Analysis, Writing – review and editing. LY: Formal Analysis, Writing – review and editing. XW: Formal Analysis, Writing – review and editing. BY: Conceptualization, Writing – review and editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K., et al. (2022). Saracatinib, a selective src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 206 (12), 1463–1479. doi:10.1164/rccm.202010-3832OC
Antar, S. A., Ashour, N. A., Marawan, M. E., and Al-Karmalawy, A. A. (2023). Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int. J. Mol. Sci. 24 (4), 4004. doi:10.3390/ijms24044004
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390 (6), 497–509. doi:10.1056/NEJMoa2309000
Kim, H. K., Kim, S. J., Gil, W. J., and Yang, C. S. (2025a). Exploring the therapeutic potential of phytochemicals: challenges and strategies for clinical translation. Phytomedicine 145, 157090. doi:10.1016/j.phymed.2025.157090
Kim, T. R., Son, B., Lee, C. G., and Park, H. O. (2025b). Amphiregulin in fibrotic diseases and cancer. Int. J. Mol. Sci. 26 (14), 6945. doi:10.3390/ijms26146945
Kuete, J. B. T., Kuete, J. R. N., Mbaveng, A. T., Kuete, V., Efferth, T., and Weiskirchen, R. (2025). A three-year review (2023-2025) on the effectiveness of natural products from plants in treating major types of fibrosis. Phytomedicine 148, 157242. doi:10.1016/j.phymed.2025.157242
Li, X., She, J., Cai, M., Chen, X., Qiu, R., Luo, X., et al. (2025). New polyketides from a marine sponge-derived fungus, neopestalotiopsis sp., with anti-renal fibrosis activity. Mar. Drugs 23 (4), 148. doi:10.3390/md23040148
Liu, H., Jin, X., Liu, S., Liu, X., Pei, X., Sun, K., et al. (2025a). Recent advances in self-targeting natural product-based nanomedicines. J. Nanobiotechnology 23 (1), 31. doi:10.1186/s12951-025-03092-9
Liu, X., Dou, B., Zhu, Q., and Liu, C. (2025b). Targeting the programmed cell death signaling mechanism with natural products for the treatment of acute pancreatitis: a review. Front. Pharmacol. 16, 1567552. doi:10.3389/fphar.2025.1567552
Keywords: fibrosis, natural products, traditional Chinese medicine, medicinal plants, drug development
Citation: Qian H, Tao X, Yuan L, Wang X and Yu B (2025) Editorial: Applications of medicinal plants and their metabolites in fibrotic disease: novel strategies, mechanisms, and their impact on clinical practice. Front. Pharmacol. 16:1711009. doi: 10.3389/fphar.2025.1711009
Received: 23 September 2025; Accepted: 27 October 2025;
Published: 07 November 2025.
Edited by:
Javier Echeverria, University of Santiago, ChileReviewed by:
Ahmed A. Al-Karmalawy, University of Mashreq, IraqFrancisco Cruz-Sosa, Universidad Autónoma Metropolitana, Mexico
Copyright © 2025 Qian, Tao, Yuan, Wang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bing Yu, c21tdWNlbGx5dUAxNjMuY29t